Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia

Gynecological Endocrinology

Volumn 24, Issue 4, 2008, Pages 207-213

  Dane, Cem ^a,b   Dane, Banu ^a   Cetin, Ahmet ^a   Erginbas, Murat ^a  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Emlakbank Bloklari B:1 D:12 ^*  (Turkey)

Author keywords

Biochemical marker; Bone turnover; Osteopenia; Osteoporosis; Risedronate; Urinary CTx

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; RISEDRONIC ACID; VITAMIN D;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DYSPEPSIA; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NAUSEA; OSTEOLYSIS; OSTEOPENIA; OUTCOME ASSESSMENT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; WORLD HEALTH ORGANIZATION;

AGED; ALGORITHMS; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE RESORPTION; COLLAGEN TYPE I; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; TREATMENT OUTCOME;

EID: 41649102413     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590801895617     Document Type: Article

References (26)

1. Srivastava AK, Vliet EL, Lewiecki EM, Maricic M, Abdelmalek A, Gluck O, Baylink DJ. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 2005;21:1015-1026.
2. Rosen CJ, Chesnut CH, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-1910.
3. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997;7:390-406.
4. Leung JY, Ho AY, Ip TP, Lee G, Kung AW. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. Bone 2005;36:358-364.
5. Raisz L, Smith JA, Trahiotis M, Fall P, Shoukri K, Digennaro J, Sacco-Gibson N. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 2000;11:615-620.
6. Ravn P, Thompson DE, Ross PD, Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 2003;33:150-158.
7. Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 2000;26:505-511.
8. Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998;13:1124-1133.
9. World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Technical report series no. 843. Geneva: World Health Organization; 1994. pp 1-129.
10. Branton R, Percival DA. Expressing biochemical markers of bone turnover as T-scores using Osteosal™, a rapid point of care test. J Bone Miner Res 1999;14:S371.
11. Ilter E, Karalok H, Tufekci EC, Batur O. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis. Climacteric 2006;9:129-134.
12. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864-868.
13. Bjarnason NH, Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 2000;26:561-569.
14. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Akesson K, Obrant KJ. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004;19:386-393.
15. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004;19:394-401.
16. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Bréart G, Meunier PJ, Delmas PD. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 1996;11:1531-1538.
17. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-1592.
18. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-1056.
19. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
20. Hannon RA, Branton R, Percival DA, Hibbert DL, Naylor KE, Machado AB, Eastell R. Comparison of measurement of urinary CrossLaps by Osteosal, a rapid point of care test and by ELISA. Bone 1998;23:S630.
21. Percival DA, Chard M, Dawson C, Christrau S, Christiansen C. Measurement of urinary CrossLaps in patients treated with alendronate and Trisequens using the Osteosal rapid point of care test. Bone 1998;23:S628.
22. Seibel MJ. Biochemical markers of bone turnover, Part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 2006;27:123-138.
23. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL. Serum CTx: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-103.
24. Fall PM, Kennedy D, Smith JA, Seibel MJ, Raisz LG. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos Int 2000;11:481-485.
25. Hosking D, Adami S, Felsenberg D, Andia JC, Välimäki M, Benhamou L, Reginster JY, Yacik C, Rybak-Feglin A, Petruschke RA, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003;19:383-394.
26. Braga de Castro-Machado A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999;14:602-608.